References of "Leukemia Research"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailAdequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients wih lower risk myelodysplastic syndromes
Delforge, Michel; Selleslag, Dominik; BEGUIN, Yves ULg et al

in Leukemia Research (2014), 38

Background: Most patients with myelodysplastic syndromes (MDS) require transfusions at the risk of ironoverload and associated organ damage, and death. Emerging evidence indicates that iron chelation ther ... [more ▼]

Background: Most patients with myelodysplastic syndromes (MDS) require transfusions at the risk of ironoverload and associated organ damage, and death. Emerging evidence indicates that iron chelation ther-apy (ICT) could reduce mortality and improve survival in transfusion-dependent MDS patients, especiallythose classified as International Prognostic Scoring System (IPSS) Low or Intermediate-1 (Low/Int-1).Methods: Follow-up of a retrospective study. Sample included 127 Low/Int-1 MDS patients from 28 centersin Belgium. Statistical analysis stratified by duration (≥6 versus <6 months) and quality of chelation (adequate versus weak). Results: Crude chelation rate was 63% but 88% among patients with serum ferritin ≥1000 g/L. Of the 80chelated patients, 70% were chelated adequately mainly with deferasirox (26%) or deferasirox followingdeferoxamine (39%). Mortality was 70% among non-chelated, 40% among chelated, 32% among patientschelated ≥6 m, and 30% among patients chelated adequately; with a trend toward reduced cardiacmortality in chelated patients. Overall, median overall survival (OS) was 10.2 years for chelated and 3.1years for non-chelated patients (p < 0.001). For patients chelated ≥6 m or patients classified as adequatelychelated, median OS was 10.5 years. Mortality increased as a function of average monthly transfusionintensity (HR = 1.08, p = 0.04) but was lower in patients receiving adequate chelation or chelation ≥6 m(HR = 0.24, p < 0.001). Conclusion: Six or more months of adequate ICT is associated with markedly better overall survival. Thissuggests a possible survival benefit of ICT in transfusion-dependent patients with lower-risk MDS. [less ▲]

Detailed reference viewed: 46 (1 ULg)
Full Text
Peer Reviewed
See detailFacilitating studies of cell proliferation in chronic lymphocytic leukemia
Macallan, Derek C.; Defoiche, Julien; Willems, Luc ULg

in Leukemia Research (2010), 34

Detailed reference viewed: 20 (3 ULg)
Full Text
Peer Reviewed
See detailTARC and IL-5 expression correlates with tissue eosinophilia in peripheral T-cell lymphomas.
Thielen, Caroline ULg; Radermacher, Vincent ULg; Trimeche, Mounir et al

in Leukemia Research (2008), 32(9), 1431-8

The current study attempts to characterize the eosinophilia associated with T-cell lymphomas and to investigate its possible relationship with the secretion of eosinophil-stimulating factors by lymphoma ... [more ▼]

The current study attempts to characterize the eosinophilia associated with T-cell lymphomas and to investigate its possible relationship with the secretion of eosinophil-stimulating factors by lymphoma cells and/or intra-tumoral surrounding cells. Paraffin-embedded specimens from 50 patients diagnosed with peripheral T-cell lymphomas, either unspecified (PTCL-U, n=30) or angioimmunoblastic (AITL, n=20) were morphologically assessed for intra-tumoral eosinophilia and analyzed by immunohistochemistry using specific antibodies directed against TARC, IL-5, RANTES, and eotaxin. The AITL and PTCL-U cases contained a mean of 147+/-41 and 102+/-37 eosinophils per 10 high power fields, respectively. Thirty-two of 47 cases (68%) showed IL-5-positive lymphoma cells while 15/50 (30%) tumors showed variable staining for TARC in scattered non-lymphoid cells with dendritic morphology. TARC and IL-5-positive cases possessed significantly more eosinophils. Our data indicate that IL-5 and TARC expression highly correlate with eosinophilia in T-cell lymphomas, suggesting that these chemokines are involved in the recruitment of eosinophils into the tumors. [less ▲]

Detailed reference viewed: 35 (3 ULg)
Full Text
Peer Reviewed
See detailStem cell transplantation in ALL : a donor versus no donor comparison in the EORTC ALL-4 study
Labar, Boris; Suciu, S.; Muus, P. et al

in Leukemia Research (2007)

Detailed reference viewed: 24 (4 ULg)
Peer Reviewed
See detailExperimental Transmission Of Enzootic Bovine Leukosis To Cattle, Sheep And Goats - Infectious Doses Of Blood And Incubation Period Of The Disease
Mammerickx, M.; Portetelle, Daniel ULg; Declercq, K. et al

in Leukemia Research (1987), 11(4),

Detailed reference viewed: 42 (0 ULg)
Peer Reviewed
See detailAbnormal splenic megakaryopoiesis in MPSV-induced myeloproliferative disease.
Le Bousse-Kerdiles, M. C.; Fernandez-Delgado, R.; Smadja-Joffe, F. et al

in Leukemia Research (1987), 11(9), 781-7

The myeloproliferative sarcoma virus (MPSV) induces a murine myeloproliferative syndrome characterized by an erythromyelemia, an anemia, a thrombocytopenia associated with a myeloproliferation in the ... [more ▼]

The myeloproliferative sarcoma virus (MPSV) induces a murine myeloproliferative syndrome characterized by an erythromyelemia, an anemia, a thrombocytopenia associated with a myeloproliferation in the spleen and a splenic and medullar fibrosis. We have used the in-vitro plasma clot technique to measure megakaryocytic precursors in the spleen and bone-marrow of MPSV-infected mice. We report that megakaryocytic colonies are increased, in number (X75), in concentration (X9) and in size, in the spleen but not in the bone-marrow of neoplastic mice. Furthermore, these splenic precursors are hypersensitive to growth factors present in the anemic mouse serum used in the culture system. These data show that the thrombocytopenia observed in the MPSV-induced neoplasia does not result from a lack of megakaryocyte precursors, but rather from an excess of megakaryocyte destruction. This ineffective splenic megakaryopoiesis associated with the presence of a massive splenic fibrosis make the MPS-induced neoplasia a suitable model for studying the perturbation of megakaryopoiesis in myeloproliferative syndrome associated with fibrosis. [less ▲]

Detailed reference viewed: 7 (1 ULg)
Peer Reviewed
See detailPhenotype of thymic lymphomas in the mouse.
Greimers, Roland ULg; Rongy, Anne Michel; Defresne, Marie-Paule ULg et al

in Leukemia Research (1986), 10(7), 777-82

The MP2 cell line was established from a murine leukemia virus-induced thymic lymphoma. Half of the cells were consistently L3T4 positive and less than 5% of the cells were Lyt-2 positive. Single cell ... [more ▼]

The MP2 cell line was established from a murine leukemia virus-induced thymic lymphoma. Half of the cells were consistently L3T4 positive and less than 5% of the cells were Lyt-2 positive. Single cell cloning on the basis of the presence or absence of Lyt-2 allowed the isolation of four clones with stable phenotypes: (1) Lyt-2-, L3T4-; (2) Lyt-2+, L3T4+; (3) Lyt-2-, L3T4+; (4) Lyt2+, L3T4-. These data are discussed in relation to tumour cell heterogeneity and to normal T-cell differentiation pathways. [less ▲]

Detailed reference viewed: 39 (0 ULg)
Peer Reviewed
See detailLoss of one Ha-rasl allele in some human colorectal tumours
Lambert, S. A.; Martial, Joseph ULg; Winkler, Rose ULg

in Leukemia Research (1986), 10

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailSecond tumors and myeloproliferative diseases after Hodgkin's disease treatment
Andrien, F.; Lemaire, M.; Beguin, Yves ULg et al

in Leukemia Research (1986), 10

Detailed reference viewed: 24 (2 ULg)
Peer Reviewed
See detailEpitopes of BLV glycoprotein gp51 recognized by sera infected cattle and sheep
Bruck, Claudine; Portetelle, Daniel ULg; Mammerickx, Marc et al

in Leukemia Research (1984), 8

Detailed reference viewed: 13 (0 ULg)
Peer Reviewed
See detailGenomic integration of bovine leukemia provirus and lack of viral RNA expression in the target cells of cattle with different responses to BLV infection.
Kettmann, Richard; Marbaix, Gérard; Cleuter, Yvette et al

in Leukemia Research (1980), 4

Detailed reference viewed: 8 (1 ULg)